Recovery of Resistant Alopecia Areata Treated with Tofacitinib

Abstract

Tofacitinib has been reported to activity in the recovery of alopecia areata (AA) in several reports, mainly from Western countries. We report the case of a young Indian boy with resistant AA who was treated with tofacitinib-based therapy. Improvements in terms of hair regrowth were observed within 6–8 weeks of treatment with oral tofacitinib 2.5 mg BID tablets, and the hair regrowth was nearly complete by 5 months. There were no associated side effects and the treatment with tofacitinib was well-tolerated.

Abrocitinib Improved Dupilumab-Resistant Severe Atopic Dermatitis with Comorbid Mild Alopecia Areata in a 12-Year-Old Boy: A Case Report with 1-Year Follow-Up

“…18 Based on this review, we have summarized the latest reports of JAK inhibitor treatment for pediatric AA in the past 2 years (Table 1). 18,[20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35] Six cases involved the use of upadacitinib (selective JAK1 inhibitor) and abrocitinib (selective JAK1 inhibitor) in treating pediatric patients with AA, showing good tolerability. 18,[31][32][33][34][35] Upadacitinib and abrocitinib have been approved for severe AD in children aged ≥12 years.…”